January 08, 2025--(BUSINESS WIRE)--MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced the in ...

MOMA-313 is under clinical development by Moma Therapeutics and currently in Phase I for Metastatic Pancreatic Cancer.

Rounding out the C-suite as chief scientific officer is Christoph Lengauer, another ex-Third Rock partner and co-founder of MOMA Therapeutics, Celsius Therapeutics, and Thrive Earlier Detection ...

In January 2024, the Swiss pharma penned a $66 million upfront agreement to access Moma Therapeutics’ KnowledgeBase ADC platform across various cancers. That deal also came with the promise of $ ...